Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)

NCT01972789 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

349

Enrollment

INDUSTRY

Sponsor class

Conditions

Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD

Interventions

DRUG: Ranibizumab

Sponsor

Novartis Pharmaceuticals